Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/302% above fair value
$64.63−1.20 (-1.82%)
Close on Nov 20, 2026Market cap $15.77BP/E 19.4Yield –
Exelixis free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Exelixis's free cash flow for the twelve months ending Oct 2, 2026 was $1.16B, up 48.9% year over year. For fiscal 2025 it was $875.84M, up 30.4% from the year before. The highest annual figure on record is $875.84M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $875.84M | +30.4% |
| FY2024 | Jan 3, 2025 | $671.54M | +129.3% |
| FY2023 | Dec 29, 2023 | $292.86M | -12.6% |
| FY2022 | Dec 30, 2022 | $334.91M | -3.4% |
| FY2021 | Dec 31, 2021 | $346.58M | +94.0% |
| FY2020 | Jan 1, 2021 | $178.64M | -65.3% |
| FY2019 | Jan 3, 2020 | $514.12M | +34.4% |
| FY2018 | Dec 28, 2018 | $382.42M | +164.7% |
| FY2017 | Dec 29, 2017 | $144.47M | -30.8% |
| FY2016 | Dec 31, 2016 | $208.70M | – |
| FY2015 | Dec 31, 2015 | -$141.50M | – |
| FY2014 | Dec 31, 2014 | -$235.88M | – |
| FY2013 | Dec 31, 2013 | -$200.94M | – |
| FY2012 | Dec 31, 2012 | -$125.86M | – |
| FY2011 | Dec 31, 2011 | -$160.22M | – |
| FY2010 | Dec 31, 2010 | -$102.86M | – |
| FY2009 | Dec 31, 2009 | -$20.50M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Oct 2, 2026 | $277.47M | -3.9% |
| Q2 FY2026 | Jul 3, 2026 | $300.93M | +552.0% |
| Q1 FY2026 | Apr 3, 2026 | $250.34M | +20.1% |
| Q4 FY2025 | Jan 2, 2026 | $332.36M | +40.7% |
| Q3 FY2025 | Oct 3, 2025 | $288.84M | +9.8% |
| Q2 FY2025 | Jul 4, 2025 | $46.16M | -59.1% |
| Q1 FY2025 | Apr 4, 2025 | $208.49M | +252.6% |
| Q4 FY2024 | Jan 3, 2025 | $236.29M | – |
| Q3 FY2024 | Sep 27, 2024 | $263.14M | +143.7% |
| Q2 FY2024 | Jun 28, 2024 | $112.98M | -1.8% |
| Q1 FY2024 | Mar 29, 2024 | $59.13M | -18.3% |
| Q4 FY2023 | Dec 29, 2023 | -$2.56M | -104.0% |
| Q3 FY2023 | Sep 29, 2023 | $107.99M | +2.8% |
| Q2 FY2023 | Jun 30, 2023 | $115.04M | +383.5% |
| Q1 FY2023 | Mar 31, 2023 | $72.38M | -49.1% |
| Q4 FY2022 | Dec 30, 2022 | $63.98M | -29.3% |
| Q3 FY2022 | Sep 30, 2022 | $105.03M | +52.6% |
| Q2 FY2022 | Jul 1, 2022 | $23.79M | -85.2% |
| Q1 FY2022 | Apr 1, 2022 | $142.11M | +446.9% |
| Q4 FY2021 | Dec 31, 2021 | $90.49M | +376.2% |
| Q3 FY2021 | Oct 1, 2021 | $68.81M | +482.7% |
| Q2 FY2021 | Jul 2, 2021 | $161.29M | +70.3% |
| Q1 FY2021 | Apr 2, 2021 | $25.99M | -51.1% |
| Q4 FY2020 | Jan 1, 2021 | $19.00M | -87.4% |
| Q3 FY2020 | Oct 2, 2020 | $11.81M | -83.9% |
| Q2 FY2020 | Jul 3, 2020 | $94.71M | -27.4% |
| Q1 FY2020 | Apr 3, 2020 | $53.11M | -66.7% |
| Q4 FY2019 | Jan 3, 2020 | $150.76M | +48.2% |
| Q3 FY2019 | Sep 27, 2019 | $73.56M | -50.8% |
| Q2 FY2019 | Jun 28, 2019 | $130.52M | +109.7% |
| Q1 FY2019 | Mar 29, 2019 | $159.29M | +131.3% |
| Q4 FY2018 | Dec 28, 2018 | $101.70M | +185.2% |
| Q3 FY2018 | Sep 28, 2018 | $149.64M | +307.6% |
| Q2 FY2018 | Jun 29, 2018 | $62.23M | +1440.0% |
| Q1 FY2018 | Mar 30, 2018 | $68.86M | +1.2% |
| Q4 FY2017 | Dec 29, 2017 | $35.66M | -57.8% |
| Q3 FY2017 | Sep 30, 2017 | $36.71M | – |
| Q2 FY2017 | Jun 30, 2017 | $4.04M | – |
| Q1 FY2017 | Mar 31, 2017 | $68.05M | – |
| Q4 FY2016 | Dec 31, 2016 | $84.52M | – |
See a number that looks wrong?